Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in arms of the study, in which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) followed by the addition of narlaprevir, 85-87 percent of patients achieved rapid virologic response (RVR), compared to 58-75 percent of patients in the no lead-in narlaprevir arms and no patients in the PEGINTRON and REBETOL control arm. RVR, defined in this study as undetectable virus (HCV RNA) at week 4 of narlaprevir treatment, is recognized as an important predictor for achieving sustained virologic response. These interim results from the NEXT-1 study were reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.[1]

"These interim results, while preliminary, are very encouraging, and showed that narlaprevir has potent antiviral activity in hepatitis C," said John Vierling, M.D., professor of medicine and surgery, chief of hepatology, Baylor College of Medicine, Houston, and the lead investigator of the study. "In this study, once-daily narlaprevir greatly improved viral clearance at week 4 of treatment in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Importantly, patients in the lead-in narlaprevir arms also achieved improved rates of early virologic response (EVR), defined as undetectable virus at week 12 of treatment, with 85-87 percent of patients having undetectable
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... ANGELES , Sept. 19, 2014  CytRx Corporation ... development company specializing in oncology, today announced that ... present at BioCentury,s 2014 NewsMakers in the Biotech Industry ... Eastern Time. The conference will take place at the ... . A live and archived webcast ...
(Date:9/19/2014)... , Sept. 19, 2014  PCI is pleased ... (Biotec).  Biotec is a leading provider of Clinical ... in Bridgend, Wales in ... addition significantly expands PCI,s presence in the UK/EU ... by adding packaging, storage and distribution capacity, as ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... Dec. 29, 2010 Reportlinker.com announces that a ... catalogue: Women,s Health Diagnostic Testing ... The purpose of this TriMark Publications report is ... vitro diagnostics (IVDs) market called women,s health testing. ...
... Reportlinker.com announces that a new market research report ... The Outlook for Pharmaceuticals in Central Asia ... Outlook for Pharmaceutical Markets in Asia is a ... Intelligence. Each report provides individual and highly-detailed analysis ...
Cached Medicine Technology:Reportlinker Adds Women's Health Diagnostic Testing 2Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 2Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 3
(Date:9/19/2014)... kids transition from elementary to middle school, they are ... study. But the researchers studying U.S schoolkids ... physical bullying declines as students get older. Because ... address all types of bullying as well as differences ... The study was published recently in School Psychology ...
(Date:9/19/2014)... 19, 2014 Hastings and Hastings, a discount ... the industry, announces a record number of visitors to its ... variety of serious injury cases as well as auto accident ... bite related accident cases and others. Having served the state ... stood the test of time when it comes to dedicated ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... -- Your brain structure could help predict how willing you ... Researchers at Yale University found those with greater volume in ... may be more likely to engage in risky behavior than ... study, funded by the U.S. National Institute on Aging, involved ... the Northeast. The researchers sought to determine how brain structure ...
(Date:9/19/2014)... 2014 (HealthDay News) -- The U.S. Food and Drug Administration ... Trulicity is part of a class of once-a-week injectable drugs ... 2 diabetes. "Trulicity is a new treatment option, ... regimens to control blood sugar levels in the overall management ... the FDA,s Office of Drug Evaluation II, said in an ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... child filed a motion in federal court today to confirm settlement ... The family alleged in the suit that the insurer wrongfully ... (ASD), on the baseless ground that the care was "experimental." ... at a court-ordered conference on Wednesday, June 17, 2009, Blue Cross ...
... between gray matter and dopamine levels in patients , ... levels of the neurotransmitter dopamine may explain brain gray ... study suggests. , Previous research found an association between ... wasn,t known, the researchers wrote. , In this new ...
... treatment delays and jeopardize care, review suggests, , FRIDAY, June ... lecturer at the University of Toronto, was enjoying a rare ... beeped. , "I answered the page, and there was the ... been calling repeatedly to try to get in touch with ...
... , Brio Active opens its doors this month, offering a ... its core. , , DENVER, June 19 Brio ... vibration, a relatively new fitness concept in the U.S., with ... strength, flexibility, balance, energy, bone density, and neuromuscular coordination. ...
... 19 Bertalan Mesko, medical blogger and health 2.0 consultant, ... by Federico Semeraro, MD and the D-Sign Team, that provides ... but not everyone is trained to be able to perform ... to do it through clear instructions and images. , ...
... WHITE PLAINS, N.Y., June 19 Kenneth A. May, former CEO ... Trustees of the March of Dimes, it was announced today. , ... for our mission, especially our Prematurity Campaign," said Dr. Jennifer L. ... Ken,s continued leadership as we work towards our goal of giving ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 3Health News:Pages to Doctors Don't Always Hit the Mark 2Health News:Pages to Doctors Don't Always Hit the Mark 3Health News:Brio Active Brings Whole Body Vibration Fitness to Cherry Hills Village 2
A CDI original design with seams on the outside, away from the skin, adjustable fit and removable/adjustable back strap, provides patient comfort and needed compression....
Ideal for autoplasty and liposuction of chin and cheeks...
Applies pressure on scalp to stretch it before surgery...
Chin Support...
Medicine Products: